Mounjaro for diabetes: what the side-effect evidence actually shows

What the SURPASS trials found, and what that means day to day

The SURPASS clinical programme studied tirzepatide specifically in adults with type 2 diabetes, across thousands of participants. The most frequently reported side effects were gastrointestinal: nausea affected roughly 12–20% of participants depending on dose and trial arm, with diarrhoea and vomiting also common, particularly in the first month. Most events were mild to moderate. The NHS guidance on tirzepatide describes this pattern clearly and is worth reading in full before starting treatment.

Gastric emptying slows noticeably on tirzepatide, which is part of how it works. Eating smaller portions and avoiding very fatty or spicy meals during the early weeks helps many people manage nausea without stopping treatment. A useful one-minute habit: run your eye down what you ate in the hour before any new symptom appeared, food triggers are often obvious once you look for them, and spotting the pattern early gives you something concrete to discuss with your prescriber.

Injection-site reactions (redness, bruising, itching) occur in a small proportion of users. Rotating between the abdomen, thigh and upper arm reduces this. Fatigue and headache are also reported, usually settling as your body adjusts.

The diabetes-specific risk: blood sugar and medicines that interact

People using Mounjaro for type 2 diabetes face one side-effect consideration that doesn't apply to those using it for weight management alone: hypoglycaemia. Tirzepatide lowers blood glucose, and if it's combined with insulin or a sulfonylurea, the combined effect can push blood sugar too low. Symptoms (shakiness, sweating, rapid heartbeat, confusion) need prompt attention.

The BNF entry for tirzepatide flags this interaction clearly, and your prescriber should review your full medicine list before starting. If you're on insulin, your dose is often reduced when tirzepatide begins; this should always be led by your diabetes team, not adjusted independently. The broader safety picture for people with type 2 diabetes using tirzepatide is covered thoroughly on our page on Mounjaro safety for people with diabetes.

Kidney function can also be affected indirectly. Severe vomiting or diarrhoea leads to dehydration, which puts pressure on the kidneys, this is worth acting on quickly rather than waiting it out. Stay hydrated, and if GI symptoms are severe and prolonged, contact a clinician the same day.

Serious but rare risks: pancreatitis and what to watch for

In January 2026 the MHRA published a Drug Safety Update drawing attention to acute pancreatitis across the GLP-1 medicine class, including tirzepatide. The signal isn't new (it appears in the prescribing information) but the update reinforced what symptoms should prompt same-day or emergency care: severe, persistent stomach pain, especially pain that spreads to the back, with or without vomiting. Do not wait to see if it passes. You can report any suspected adverse effect directly to the MHRA via the Yellow Card scheme.

A personal or family history of medullary thyroid carcinoma or MEN2 syndrome means tirzepatide is contraindicated; a history of pancreatitis or certain gastrointestinal conditions requires careful prescriber review before treatment starts. None of these rules out assessment, they shape the clinical conversation.

For a broader look at how the side-effect profile compares in people without a diabetes diagnosis, the Mounjaro side effects for non-diabetics page sets out what differs and why, and if you are also wondering whether Mounjaro is safe for people without diabetes, that question is addressed in detail there too. And if you want the full side-effect picture for Mounjaro regardless of indication, our main Mounjaro side effects guide covers the complete range of effects documented in trials and post-market reporting.

Pregnancy, contraception and situations that need specialist input

Mounjaro is not recommended during pregnancy, while breastfeeding, or if conception is being actively planned. This applies whether it's prescribed for diabetes or weight management. For women using oral contraceptives, the MHRA and NHS guidance advises adding a non-oral method of contraception (such as condoms) for the first four weeks of tirzepatide treatment and for four weeks after every dose increase, because gastric slowing can reduce absorption of the pill. A prescriber or GP should discuss this before your first pen.

If you have type 1 diabetes and are wondering whether tirzepatide applies to you, the situation is different and worth reading carefully, our guide on Mounjaro and type 1 diabetes explains the current evidence and licensing position. The Mounjaro overview page is the right starting point if you want the full clinical picture in one place before a consultation.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber who considers your diabetes medicines, your kidney function, your contraception and your full health history before any treatment is recommended. There's no algorithmic shortcut. If you'd like that conversation, speak to our prescribers through a free consultation, and if you have questions in the meantime, the FAQs cover the ones we hear most often.